环孢素A联合雄激素与单用雄激素治疗国人再生障碍性贫血疗效及安全性分析  

A contrast on the effectiveness and safety between Cyclosporine A combined androgen and androgen alone for aplastic anemia in china: a meta-analysis

作　　者：杨冰雪 程单凤 邱晨希 廖建荣 刘庭波[1] Yang Bingxue;Cheng Danfeng;Qiu Chenxi;Liao Jianrong;Liu Wingbo(Department of Hematology,Fujian Provincial Key Laboratory on Hematology,Union Hospital of Fujian Medical University,Fuzhou 350001,China)

机构地区：[1]福建医科大学附属协和医院血液科福建省血液病学重点实验室福建省血液病研究所,福建福州350001

出　　处：《临床荟萃》2018年第10期889-896,903,共9页Clinical Focus

基　　金：福建省血液医学中心建设项目资助(闽政办(2017)4号);国家和福建省临床重点专科建设项目资助

摘　　要：目的评价环孢素A(Cyclosporine A,CsA)联合雄激素与单用雄激素治疗国人再生障碍性贫血(Aplastic anemia,AA)疗效与安全性。方法计算机检索中国知网,万方数据库,维普中文科技期刊数据库,纳入CsA治疗AA的随机对照试验(randomized controlled trial,RCT)文献,手工检索血液学杂志其他相关文献,对纳入的相关研究进行方法学质量评价,且采用StataSE 12.0软件进行Meta分析。结果共纳入50个RCT,共计3099例患者。Meta分析结果提示,对于总有效率和完全缓解率,试验组(CsA+雄激素)和对照组(单用雄激素)差异均有统计学意义。总有效率和完全缓解率的RR及其95%CI分别为1.37(1.31,1.43)、1.87(1.62,2.15)。结论 CsA联合雄激素与单用雄激素相比,可以提高国人AA患者的临床疗效。Objective To assess the efficacy and safety of Cyclosporine A（CsA） combined androgen and androgen alone in the treatment of Aplastic Anemia （AA） with Chinese patients.Methods Randomized controlled trails （RCT） of CsA for AA were collected from CNKI, WANFANG, and VIP. Other relevant hematological journals were also hand searched. The methodological quality of included studies was evaluated, and data analyses were performed with the software StataSE 12.0 .Results A total of 50 RCT with 3099 patients were included.The meta-analysis showed that,as for the total effective rate and complete remission rate, significant differences were noted between CsA＋ androgen and androgen alone, [total effective rate： RR and 95% CI were 1.37 （ 1.31 to 1.43 ）; complete remission rate： RR and 95% CI were 1.87 （ 1.62 to 2.15 ）].Conclusion According to the domestic evidence, treatment with CsA combined androgen for AA may improve the clinical effectiveness,compared with androgen alone.

关 键 词：贫血 再生障碍性 环孢素A 雄激素 Meta分析 

分 类 号：R556.5[医药卫生—血液循环系统疾病]